The patent expires in 2019, there is not nearly enough time to develop the drug and run the Phase IIb and Phase III trials. Phase IIa was run by Amarin before the license. Nice deceptive subject line, clearly part of the scam. Yet another extremely optimistic press release by MCET.
"MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time MCT-125 is under patent protection"